Journal of Oncology Pharmacy Practice · 2000 · 26 citations · 67 references
MedicineOncologyPharmacologyCancer PharmacologyEnzymologyMolecular OncologyEnzyme InhibitionTopoisomerase InhibitorsAnticancer ActivityAnticancer ChemotherapyDna Topoisomerase Ii InhibitionEnzymesMolecular Drug ResistanceTopoisomerase ActivityTopoisomerase Ii InhibitorsTopoisomerase Inhibitor Resistance
Topoisomerase (topo) I and II are nuclear enzymes, which play a major role in the topological rearrangement of DNA during replication and transcription processes. In the course of years, many different agents have been found which can inhibit the topos and thereby exploit cytotoxicity, also against tumour cells. Selective inhibition of the topo I enzyme can, however, induce a reactive increase in topo II levels, and vice versa. This mechanism is associated with the development of drug resistance. Dual inhibition of both topo I and II may, theoretically, overcome this resistance problem. In this review, the most important and promising dual topo I/II inhibitors designed as anticancer agents will be discussed. Thus far, only the indolyl quinoline derivative TAS-103, the 7 H-benzo [ e] pyrido [4,3- b] indole derivative intoplicine, and the acridine derivative PZA have been shown to be dual topo inhibitors with high cytotoxicity.
67
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Matthew R. Redinbo, Lance Stewart, Peter Kühn et al. · Science · 1998 · 878 citations
Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
Fred H. Drake, Glenn A. Hofmann, H F Bartus et al. · Biochemistry · 1989 · 414 citations
M Tsai-Pflugfelder, Leroy F. Liu, A A Liu et al. · Proceedings of the National Academy of Sciences · 1988 · 397 citations · Full text
DNA topoisomerase I is involved in both repression and activation of transcription
Alejandro Merino, Knut Madden, William S. Lane et al. · Nature · 1993 · 379 citations